What Does Viatris’ Trio Of Attacks On US Semaglutide Mean For Wegovy Generics?
Viatris’ Spate Of Inter Partes Reviews Largely Denied, With One Upside For Firm
Viatris has failed in its attempt to begin proceedings to overturn two key semaglutide patents in the US, while succeeding on another, as part of its bid to gain early entry with its proposed generic version of Novo Nordisk’s renowned Wegovy. Generics Bulletin reviews the landscape.
